Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...

Results of a large clinical trial demonstrated the benefits of an investigational, once-a-day pill called brenso­catib as a ...

Symptoms of bronchiectasis include chronic cough with sputum (mucous) production, shortness of breath and fatigue. Acute exacerbations of the debilitating condition experienced by patients are ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Pulmonary fibrosis (PF) is a progressive interstitial lung disease (ILD) characterized by excessive fibrotic tissue ...

In addition, enrollment is ongoing in our Phase II clinical trial of nebulized Ensifentrine in non-CF bronchiectasis ... on the rate and risk of pulmonary exacerbations, symptoms and quality ...

Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at ... bronchitis, acute sinusitis and headache. All were mild-to-moderate ...

Acute and chronic lower respiratory tract conditions ... especially when patients are nonresponsive, have frequent exacerbations, or return with worsening, progressive symptoms.

The company expects to launch Brensocatib for non-cystic fibrosis bronchiectasis (NCFBE) in 2025. In a Phase 3 clinical trial, the drug achieved a 20% reduction in pulmonary exacerbations and an ...